Introduction {#S0001}
============

Gastric cancer (GC) is one of the most common and lethal malignancies worldwide.[@CIT0001] Early detection and a timely radical surgical resection are so far the optimal treatment for GC.[@CIT0002] However, it is clinically difficult to diagnose an early-stage GC due to its commonly asymptomatic feature.[@CIT0003] A recent meta-analysis showed that endoscopic screening may reduce the risk of death from GC in Asian populations.[@CIT0004] However, most GC patients have been in their advanced stage at the time of diagnosis and lost the chance of radical surgery due to the low popularity and availability of endoscopic screening in China.[@CIT0005]

The current therapeutic principle for locally advanced gastric cancer (LAGC) is multidisciplinary with surgical procedures as the core.[@CIT0006] For potentially resectable cases, neoadjuvant chemotherapy (NAC) may help decrease the tumor stage and eliminate occult micrometastasis so as to improve the R0 resection rate.[@CIT0007],[@CIT0008] In addition, part of the initially unresectable LAGC patients can be successfully converted to resectable cases by NAC and then undergo curative surgery.[@CIT0009] In the past decades, several clinical trials have been conducted to assess the efficacy and safety of NAC for LAGC.[@CIT0010],[@CIT0011]

The MAGIC trial published in 2006 is regarded as the landmark to uncover the effectiveness of NAC regimens for LAGC, saying that perioperative chemotherapy with epirubicin, cisplatin and fluorouracil (ECF) could improve overall survival (OS) vs surgery alone in patients with non-metastatic stage II and higher GC.[@CIT0012] Also, another multicenter randomized controlled trial (RCT) reported that NAC with cisplatin and 5-FU could increase the survival of patients with resectable gastroesophageal adenocarcinoma, as compared with surgery alone.[@CIT0013] Furthermore, the FLOT4-AIO trial demonstrated that the combination of docetaxel, oxaliplatin, leucovorin and 5-FU (FLOT) was superior to the ECF regimen as NAC for resectable advanced GC.[@CIT0014] However, the inconvenience of continuous intravenous (IV) 5-FU infusion limits the use of this regimen worldwide as a popular chemotherapeutic regimen. Therefore, the consensus for the optimal NAC regimen for GC is still far from being reached.[@CIT0015]

Two cytotoxic drugs are preferred for advanced GC and three-drug regimens are reserved for medically fit patients according to the NCCN guidelines.[@CIT0016] Accordingly, combination of S-1 and cisplatin/oxaliplatin has long been used as the standard chemotherapy regimen under adjuvant, neoadjuvant and palliative settings for GC in East Asia.[@CIT0017]--[@CIT0019] However, peritoneal metastasis remains highly prevalent in advanced GC even under S-1 and oxaliplatin therapy.[@CIT0020] Intravenous administration of docetaxel can effectively penetrate ascites; thus, a NAC regimen involving docetaxel would be helpful for eliminating peritoneal metastasis.[@CIT0021] Therefore, we designed this study to investigate the efficacy and safety of docetaxel, oxaliplatin and S-1 (DOS) vs oxaliplatin and S-1 (SOX) as NAC for potentially resectable LAGC.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

This retrospective cohort study was designed to compare the efficacy and safety of DOS vs SOX as a NAC regimen for patients with potentially resectable locally advanced GC (LAGC). Clinical data used in this study were obtained from the medical records of both inpatients and outpatients in the Department of gastrointestinal surgery, Changzheng Hospital affiliated to the Second Military Medical University (Shanghai, China). In addition, patients or relatives were contacted via telephone or Wechat for cases that lacked information. All participants included in this study signed written informed consent for their medical information to be used for uncommercial scientific research. Propensity score-matched (PSM) analysis was used to match the two groups on a 1:1 basis. This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Changzheng Hospital, Second Military Medical University.

Inclusion and Exclusion Criteria {#S0002-S2002}
--------------------------------

Both male and female patients aged 18--75 years with histologically confirmed gastric adenocarcinoma between January 2010 and January 2018 were eligible for inclusion. The eligibility criteria were as follows: 1) clinical staging as T2-4bN0-3M0 based on the 7th American Joint Committee on Cancer (AJCC) staging system; 2) receiving NAC of either DOS or SOX regimen; and 3) Eastern Cooperative Oncology Group (ECOG) score 0--1 point.

Patients were excluded from the study if they met any of the following criteria: 1) contemporaneous existence or a previous history of other malignancies; 2) gastric stump cancer; 3) received preoperative radiotherapy; 4) existence of distant metastasis including retroperitoneal lymph node, left supraclavicular lymph node, liver, lung or bone metastasis; 5) peritoneal dissemination by laparoscopic screening; and 6) uncontrolled systemic diseases.

Preoperative Evaluation and Staging {#S0002-S2003}
-----------------------------------

All patients underwent abdominal and pelvic contrast-enhanced computed tomography (CT) and/or endoscopic ultrasonography to acquire preoperative staging. For patients stage T3N1 or above, or who were suspected as having peritoneal metastasis, laparoscopic exploration was routinely performed to further accurate staging unless the patient was medically unfit.

Neoadjuvant Chemotherapy {#S0002-S2004}
------------------------

DOS: Docetaxel at 75 mg/m^2^ and oxaliplatin at 130 mg/m^2^ were administered IV on day 1, and S-1 was administered orally at 80 mg/d/m^2^ (body surface area \<1.25 m^2^), 100mg/d/m^2^ (1.25 m^2^≤body surface area \<1.5 m^2^), and 120 mg/d/m^2^ (body surface area ≥1.5 m^2^) respectively on day 1--14 of a 21-day cycle.

SOX: Oxaliplatin at 130 mg/m^2^ was administered IV on day 1, and S-1 was administered orally at 80 mg/d/m^2^ (body surface area \<1.25 m^2^), 100mg/d/m^2^ (1.25 m^2^≤body surface area \<1.5 m^2^), and 120 mg/d/m^2^ (body surface area ≥1.5 m^2^) respectively on day 1--14 of a 21-day cycle.

NAC was given as soon as the diagnosis was established and the contraindications for chemotherapy were excluded. For patients who underwent laparoscopic exploration, NAC would be given within 2 days after surgery.

Response and Toxicity Evaluation {#S0002-S2005}
--------------------------------

Treatment response of each patient was assessed using an abdominal and pelvic contrast-enhanced CT by a professional gastrointestinal radiologist based on the Response Evaluation Criteria in Solid Tumors (RECIST) guideline 1.1.[@CIT0022] NAC-related toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0,[@CIT0023] and the data indicating the most severe toxicity for each patient within the whole neoadjuvant chemotherapy course were used in the analysis.

Surgical Treatment {#S0002-S2006}
------------------

After three cycles of NAC, tumor resectability was reassessed by a multidisciplinary team (MDT). All patients identified as resectable by MDT received curative-intent surgery, including radical gastrectomy with standardized D2 lymph-node dissection. Surgery was scheduled for 3 weeks after the last dose of preoperative chemotherapy. Unresectable cases, identified by either the MDT or reevaluation of the surgeon during operation, would continue with NAC by using either the initial or alternative regimen and were defined as "unresectable" regardless of the subsequent outcome.

Postoperative Treatment and Follow-Up Observation {#S0002-S2007}
-------------------------------------------------

Patients who received R0 resection were given priority to adjuvant chemotherapy with the SOX regimen for three cycles in both groups. S-1 monotherapy was reserved for those who were unable to tolerate two-drug therapy. All patients were followed up regularly by clinic visits, telephone, or Wechat. Serum tumor biomarkers including carcinoembryonic antigen (CEA), CA19-9, CA125, and AFP were tested every 3 months for the first 2 years after surgery, and every 6 months thereafter. Chest X-ray, abdominal and pelvic contrast-enhanced CT were performed every 6 months for the first 2 years, and annually thereafter. Gastrointestinal endoscopy was conducted annually.

Statistical Analysis {#S0002-S2008}
--------------------

PSM was used to minimize the selection bias from a retrospective study on the assessed outcomes between DOS and SOX groups. The PSM was estimated by using a nonparsimonious multivariable logistic-regression model, with the NAC group as the dependent variable and all the baseline characteristics outlined in [Table 1](#T0001){ref-type="table"} as covariates. Matching was performed with a caliper of 0.05.Table 1The Baseline Demographics and Clinical CharacteristicsVariableBefore PSMAfter PSMDOS\
n=92 (%)SOX\
n=156 (%)PDOS n=90 (%)SOX n=90 (%)PGender0.9730.198 Male68 (73.9)115 (73.7)66 (73.3)58 (64.4) Female24 (26.1)41 (26.3)24 (26.7)32 (35.6)Age (years)**0.025**0.904 \<-4017 (18.5)19 (12.2)16 (17.8)17 (18.9) 41--5944 (47.8)57 (36.5)43 (47.8)40 (44.4) 60--7531 (33.7)80 (51.3)31 (34.4)33 (36.7)Tumor location0.3860.738 Upper25 (27.2)31 (19.9)25 (27.8)22 (24.4) Middle33 (35.9)58 (37.2)33 (36.7)38 (42.2) Lower34 (37.0)67 (42.9)32 (35.6)30 (33.3)Differentiation0.9950.899 Well10 (10.9)17 (10.9)10 (11.1)9 (10.0) Moderately26 (28.3)45 (28.8)26 (28.9)24 (26.7) Poorly56 (60.9)94 (60.3)54 (60.0)57 (63.3)cT staging**0.009**0.580 cT212 (13.0)44 (28.2)12 (13.3)19 (21.1) cT330 (32.6)58 (37.2)30 (33.3)26 (28.9) cT4a34 (37.0)37 (23.7)32 (35.6)30 (33.3) cT4b16 (17.4)17 (10.9)16 (17.8)15 (16.7)cN staging0.0630.949 cN018 (19.6)41 (26.3)18 (20.0)20 (22.2) cN128 (30.4)64 (41.0)28 (31.1)28 (31.1) cN222 (23.9)24 (15.4)21 (23.3)18 (20.0) cN324 (26.1)27 (17.3)23 (25.6)24 (26.7)Lauren classification0.6430.980 Intestinal36 (39.1)69 (44.2)36 (40.0)36 (40.0) Diffuse35 (38.0)58 (37.2)34 (37.8)35 (38.9) Mixed21 (22.8)29 (18.6)20 (22.2)19 (21.1)[^2][^3]

Student's *t*-test and chi-square test were used to compare continuous and categorical data respectively between the two groups. Kaplan-Meier analysis with Log rank testing was used for OS. Associated factors predictive of OS were assessed by both univariate and multivariate Cox proportional regression analyses. Values of p \<0.05 were considered statistically significant. All statistical analyses were performed by SPSS program (PASW Statistics for Windows, Version 22.0; Inc, Chicago, IL) and GraphPad Software (GraphPad Prism 5.0; La Jolla, CA, USA).

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

A total of 568 patients with histologically proven LAGC received NAC in our department between January 2010 and January 2018. After excluding 320 patients for various reasons, the remaining 248 patients were included in the initial statistical analysis, including 92 in DOS group and 156 in SOX group. Their baseline demographics and clinical characteristics are shown in [Table 1](#T0001){ref-type="table"}. The two groups were not balanced with regard to age and clinical T stage variates, and the disparities were resolved after PSM manipulation ([Table 1](#T0001){ref-type="table"}). The specific flowchart of the patients' enrollment is shown in [Figure 1](#F0001){ref-type="fig"}.Figure 1Flowchart showing the patient enrollment.**Abbreviations:** LAGC, locally advanced gastric cancer; PSM, propensity score matching; NAC, neoadjuvant chemotherapy; DOS, docetaxel, oxaliplatin and S-1; SOX, oxaliplatin and S-1.

Response to NAC {#S0003-S2002}
---------------

In the unmatched study, the overall tumor response to NAC was not statistically significant between the two groups, but an obvious trend was seen that the DOS group showed a better tumor response than the SOX group (p=0.051, [Table 2](#T0002){ref-type="table"}). Patients in DOS group achieved a higher response rate (RR, p=0.033) and a disease control rate (DCR, p=0.033). The result of PSM analysis showed that NAC with DOS was superior to SOX with respect to tumor response (p=0.005, [Table 2](#T0002){ref-type="table"}). Complete response (CR) was achieved in 7 (7.8%) and 2 (2.2%) patients in DOS and SOX groups, respectively. The RR and DCR was 80.0% and 96.7% in DOS group respectively vs 60.0% and 84.4% in SOX group.Table 2Response to NAC According to RECIST GuidelineVariableBefore PSMAfter PSMDOSSOXPDOSSOXPn=92 (%)n=156 (%)n=90 (%)n=90 (%)Response to NAC0.051**0.005**CR7(7.6)5 (3.2)7(7.8)2(2.2)PR67(72.8)101 (64.7)65(72.2)52(57.8)SD15(16.3)33 (21.2)15(16.7)22(24.4)PD3(3.3)17 (10.9)3(3.3)14(15.6)RR (CR+PR)74(80.4)106 (67.9)**0.033**72(80.0)54(60.0)**0.003**DCR (CR+PR+SD)89(96.7)139 (89.1)**0.033**87(96.7)76(84.4)**0.005**[^4][^5]

NAC-Related Adverse Events {#S0003-S2003}
--------------------------

As shown in [Table 3](#T0003){ref-type="table"}, the overall incidence of Grade 3/4 NAC-related adverse events was higher in DOS group (55.4%) than that in SOX group (34.6%) before PSM (p=0.001), and the difference was also significant after PSM (p=0.011). However, there was no NAC-related death in either group. Three patients in DOS group and one patient in SOX group dropped out of the NAC due to intolerable toxicity, showing no statistically significant difference between the two groups. The most common Grade 3/4 adverse events were leukopenia and neutropenia in both groups. Patients in DOS group experienced a higher incidence of leukopenia (27.8% vs 12.2, p=0.009) and neutropenia (38.9% vs 16.7%, p=0.001) as compared with SOX group.Table 3Grade 3/4 NAC-Related Adverse EventsEventBefore PSMAfter PSMDOS\
n=92 (%)SOX\
n=156 (%)PDOS\
n=90 (%)SOX\
n=90 (%)POverall toxicity51 (55.4)54 (34.6)0.00151 (56.7)34 (37.8)0.011Related death0 (0)0 (0)NA0 (0)0 (0)NAAborting of NAC3 (3.3)1 (0.6)0.1143 (3.3)1 (1.1)0.312Leukopenia25 (27.2)18 (11.5)0.00225 (27.8)11 (12.2)0.009Neutropenia35 (38.0)27 (17.3)\<0.00135 (38.9)15 (16.7)0.001Thrombocytopenia11 (12.0)10 (6.4)0.13010 (11.1)9 (10.0)0.808Anorexia9 (9.8)7 (4.5)0.1019 (10.0)5 (5.6)0.266Vomiting4 (4.3)4 (2.6)0.4424 (4.4)2 (2.2)0.406Neurotoxicity6 (6.5)6 (3.8)0.3436 (6.7)2 (2.2)0.148Diarrhea4 (4.3)5 (3.2)0.6424 (4.4)3 (3.3)0.700[^6]

The Surgical Resection Rate {#S0003-S2004}
---------------------------

In the unmatched study, 77 patients in DOS group underwent radical surgery, of whom 74 patients received R0 resection; of the 126 patients in SOX group who underwent radical surgery, 121 patients received R0 resection. No perceptible differences were observed in terms of the radical resection rate, R0 resection rate and residual tumor classification between the two groups ([Table 4](#T0004){ref-type="table"}). In the PSM analysis, 75 patients in DOS group underwent radical surgery, of whom 72 patients received R0 resection; of the 62 patients in SOX group underwent radical surgery, 58 patients received R0 resection. Both the radical resection rate and R0 resection rate in patients of DOS group were significantly higher than those in SOX group (83.3% vs 68.9%, p=0.023; 80.0% vs 64.4%, p=0.020) ([Table 4](#T0004){ref-type="table"}).Table 4Surgical Resection Rate for All Patients Receiving NACVariableBefore PSMAfter PSMDOS\
n=92 (%)SOX\
n=156 (%)PDOS\
n=90 (%)SOX\
n=90 (%)PRadical surgery0.5640.023 Yes77 (83.7)126 (80.8)75 (83.3)62 (68.9) No15 (16.3)30 (19.2)15 (16.7)28 (31.1)R0 resection0.5940.020 Yes74 (80.4)121 (77.6)72 (80.0)58 (64.4) No18 (19.6)35 (22.4)18 (20.0)32 (35.6)Residual tumor classification0.9460.123 R074 (80.4)121 (77.6)72 (80.0)58 (64.4) R12 (2.2)3 (1.9)2 (2.2)2 (2.2) R21 (1.1)2 (1.3)1 (1.1)2 (2.2) No surgery15 (16.3)30 (19.2)15 (16.7)28 (31.1)[^7]

Surgical and Postoperative Outcomes {#S0003-S2005}
-----------------------------------

Among the 203 patients who underwent radical surgery, no perioperative death occurred in either group. The incidence of perioperative complications and the number of total lymph nodes dissected (TLND) were both comparable between the two groups ([Table 5](#T0005){ref-type="table"}). The ypT stage and ypN stage were both similar in the unmatched analysis. However, the PSM analysis showed that the ypT stage in patients of DOS group was significantly lower than that of SOX group (p=0.043), while there was no significant difference in the ypN stage (p=0.143).Table 5Surgical Outcomes and Post-Operative PathologyVariableBefore PSMAfter PSMDOS\
n=77 (%)SOX\
n=126 (%)PDOS\
n=75 (%)SOX\
n=62 (%)PComplications9 (11.7)14 (11.1)0.99 (12.0)9 (14.5)0.664Perioperative mortality0 (0)0 (0)NA0 (0)0 (0)NATLN dissected25.4±7.025.1±6.40.76325.3±7.125.3±6.50.976ypT staging0.0780.043 ypT06 (7.8)4 (3.2)6 (8.0)2 (3.2) ypT122 (28.6)20 (15.9)22 (29.3)10 (16.1) ypT226 (33.8)47 (37.3)25 (33.3)17 (27.4) ypT315 (16.3)34 (27.0)14 (18.7)17 (27.4) ypT4a8 (10.4)21 (16.7)8 (10.7)16 (25.8)ypN staging0.1870.143 ypN039 (50.6)45 (35.7)38 (50.7)20 (32.3) ypN122 (28.6)52 (41.3)22 (29.3)21 (33.9) ypN29 (11.7)16 (12.7)8 (10.6)11 (17.7) ypN37 (9.1)13 (10.3)7 (9.3)10 (16.1)[^8]

Survival Analysis {#S0003-S2006}
-----------------

The unmatched analysis showed that the median length of follow-up was 57 (range 5--105) months. The median survival time for patients in DOS group and SOX group was 61 months and 46 months respectively, showing no statistically significant difference between the two groups (p=0.206) ([Figure 2A](#F0002){ref-type="fig"}). The 3-year survival rates in DOS group and SOX group was 64.0% and 60.7%, respectively (p=0.612); the 5-year survival rate was 50.9% and 38.8%, respectively (p=0.066). After PSM, the median length of follow-up was 58 months (range 5--105 months). Kaplan-Meier analysis revealed that DOS arm yielded better OS than the SOX arm (p=0.003) ([Figure 2B](#F0002){ref-type="fig"}). Accordingly, the median survival time for patients in DOS group and SOX group was 62 months and 41 months, respectively. The 3-year survival rate in DOS group and SOX group was 63.1% and 55.1%, respectively (p=0.288); the 5-year survival rate was 51.6% and 25.8%, respectively (p\<0.001).Figure 2Kaplan--Meier overall survival analysis. (**A**) DOS group (n=92) vs SOX group (n=156) before PSM. (**B**) DOS group (n=90) vs SOX group (n=90) after PSM. (**C**) TLND\<16 vs TLND≥16 before PSM. (**D**) TLND\<16 vs TLND≥16 after PSM.**Abbreviations:** DOS, docetaxel, oxaliplatin and S-1; SOX, oxaliplatin and S-1; TLND, total lymph node dissection.

Univariate and Multivariate Analyses of Prognostic Factors {#S0003-S2007}
----------------------------------------------------------

As shown in [Table 6](#T0006){ref-type="table"}, univariate analysis indicated that the NAC regimen, tumor differentiation, cTNM stage, Lauren classification, R0 resection rate, TLND, and NAC response were potential prognostic factors based on the PSM dataset. Multivariate analysis showed that the NAC regimen, cTNM stage, and R0 resection rate were independent prognostic factors. Patients receiving DOS NAC were associated with significant survival benefits as compared with those receiving the SOX regimen (HR, 1.905; 95% CI, 1.099--3.303, p=0.022). Besides, the worse overall survival was observed in patients with TLND less than 16 based on either unmatched (p=0.003, [Figure 2C](#F0002){ref-type="fig"}) or PSM (p=0.022, [Figure 2D](#F0002){ref-type="fig"}) population.Table 6Predictors of Mortality in PSM Analysis (n=180)VariableUnivariate AnalysisMultivariate AnalysisHR95% CIPHR95% CIPNAC regimen**0.004**0.022 DOSRefRef SOX1.7961.203--2.6811.9051.099--3.303Gender0.067 MaleRef Female0.6630.427--1.029Age (years)0.175 \<40Ref0.391--1.159 41--590.673 60--750.9820.573--1.683Tumor location0.198 UpperRef Middle1.5890.954--2.648 Lower1.2860.749--2.208Differentiation0.015 WellRef Moderately1.1320.523--2.447 Poorly2.0351.013--4.089cTNM staging\<0.001\<0.001 IIRefRef III9.8486.030--16.0858.9124.897--16.217Lauren classification0.017 IntestinalRef Diffuse1.7751.126--2.798 Mixed1.941.143--3.293 R0 resection81.36733.982--194.831\<0.00127.1687.310--100.972\<0.001TLND0.029 \<16Ref ≥160.3590.143--0.902 Complication1.7410.629--4.8150.286NAC response\<0.001 CR0.0360.009--0.152 PR0.1130.072--0.180 SDRef PD1.8150.977--3.374 NAC toxicity1.1720.788--1.7430.434[^9]

Subgroup Analysis {#S0003-S2008}
-----------------

Subgroup analysis was performed in the PSM population. No statistically significant interaction effect with the NAC regimen on survival was observed across all subgroups examined. However, variations were still detected between strata in some variables ([Figure 3](#F0003){ref-type="fig"}). Male and middle-aged (40\~59 years) were the demographic characteristics that predict a survival benefit from the DOS regimen compared with the SOX regimen. Besides, patients with well-differentiated tumors and intestinal Lauren classification were more likely to benefit from DOS as compared with SOX. In addition, patients benefited from the addition of docetaxel regardless of the clinical T stage, but those with high clinical N stage (N2-3) did not.Figure 3Subgroup analysis in the propensity score matched analysis. \*p refers to p value for interaction analysis.**Abbreviations:** DOS, docetaxel, oxaliplatin and S-1; SOX, oxaliplatin and S-1.

Discussion {#S0004}
==========

Radical resection combined with D2 lymphadenectomy has currently been widely accepted as the standard treatment for LAGC.[@CIT0024]--[@CIT0026] However, tumor recurrence and metastasis are usually inevitable in most patients, and OS in patients with advanced GC remains poor.[@CIT0027] To further improve the survival, adjuvant chemotherapy, perioperative chemotherapy, and adjuvant chemoradiation have been recommended in Asia,[@CIT0028] Europe,[@CIT0029] and the USA,[@CIT0030] respectively. In particular, NAC is a reasonable option for patients with more locally advanced disease who may be at risk of a positive resection margin under upfront surgery.[@CIT0031] The present study indicated that DOS was superior to SOX in terms of chemotherapy response, radical resection rate, R0 resection rate, and OS. Both NAC regimens were generally well tolerated, although a relatively higher overall chemotherapy-related toxicity, especially leukopenia and neutropenia, were observed in DOS group.

The potential benefit of NAC includes the early elimination of micrometastases to improve survival.[@CIT0032] More importantly, NAC could help downstage the tumor, which in turn aids in performing R0 resection in patients with potentially unresectable GC who would have been otherwise excluded from attempts at curative resection.[@CIT0033] This is especially important for patients with locally advanced large, bulky tumors or metastatic lymph nodes that are not amenable to curative resection at presentation.[@CIT0009] As reported in previous studies, the prognosis for LAGC with extensive lymph node metastasis, or bulky lymph nodes along the celiac, splenic, common hepatic, or proper hepatic arteries, remains poor even though curative resection is achieved.[@CIT0034] Therefore, in the past decades, several practice-changing clinical trials compared NAC with surgery alone and confirmed the survival benefit of NAC for LAGC.[@CIT0012],[@CIT0013] However, very few head-to-head studies have focused on direct comparison of different NAC regimens for LAGC, resulting in the diversity of recommendations that exists within the published studies and the NCCN guidelines.[@CIT0016]

The landmark study on docetaxel, cisplatin, and fluorouracil (DCF) is the V325 trial,[@CIT0035] which showed the superiority of triplet chemotherapy with DCF over doublet chemotherapy with cisplatin plus fluorouracil (CF) as a palliative therapy for patients with advanced GC. Evidence was also obtained in support of the modified DCF (mDCF) regimens with the substitution of oral 5-FU prodrugs for continuous infusion of 5-FU or the substitution of oxaliplatin for cisplatin.[@CIT0036]--[@CIT0038] Moreover, DCF/mDCF was investigated as a NAC for GC in an attempt to enhance the resection rate, which finally resulted in improved survival.[@CIT0039]--[@CIT0041] More importantly, encouraging results were witnessed in some unresectable highly advanced GC patients who obtained conversion gastrectomy following the NAC with DCF/DCS.[@CIT0042],[@CIT0043] The FLOT4-AIO trial is the only prospective randomized head-to-head trial to compare two different NAC regimens for LAGC,[@CIT0029] which showed that the FLOT regimen was associated with a better pathological response, a higher R0 resection rate, a lower post-operative pathological stage[@CIT0029] and better OS than the ECF regimen,[@CIT0014] indicating that docetaxel is an optimal surrogate for epirubicin as a component of NAC for LAGC. Collectively, these results are consistent with the present study to favor the use of DOS as a NAC for LAGC.

In contrast, two recently released Japanese studies have come to the opposite conclusion. Okabe et al[@CIT0044] reported that induction chemotherapy with DCS failed to show superiority to CS (cisplatin plus S-1) in advanced GC patients with peritoneal metastasis. Also, the JCOG1002 study explored the efficacy and safety of adding docetaxel (DCS) to the standard CS NAC therapy for LAGC with bulky lymph node and/or para-aortic lymph node metastasis. The clinical RR was 57.7%, and R0 resection was achieved in 84.6% patients.[@CIT0045] The 5-year OS and relapse-free survival (RFS) was 54.9% and 47.7%, respectively.[@CIT0046] However, considering the excellent results from JCOG0405 with CS,[@CIT0047] the author believed that DCS had no superiority to the traditional CS protocol in either short-term outcomes or long-term survival. Since only 40mg/m^2^ dose of docetaxel was given in a four-week cycle in the above two studies, the varied scheme and dosage may partially explain the discrepancies between the studies. Therefore, a high dose of docetaxel is usually needed in the neoadjuvant setting, since patients can tolerate more intense regimens and neoadjuvant treatment should have strong efficacy to maximize tumor shrinkage and prevent disease progression before surgery.

In our opinion, whether the addition of docetaxel to SOX can obtain survival benefit depends on multiple factors, including gender, age, tumor differentiation, Lauren classification, and the clinical stage, as is shown in the present study. Additionally, as R0 resection is an independent prognostic factor in our multivariate regression analysis, DOS could probably prolong the survival, at least partially, by increasing the R0 resection. This is a possible explanation for the fact that DOS did not show superiority to SOX in the palliative treatment setting. Theoretically, docetaxel is effective in restraining the locally primary tumor due to its easy transition into the peritoneal cavity and high affinity for the peritoneum.[@CIT0048] According to our practice experience, many patients showed fibrous change of the previous serosal invasion sites after NAC with no evidence of serosal invasion on postoperative pathological examination. In this circumstance, the dissemination caused by surgical manipulation would be effectively avoided. This may explain the results from our subgroup analysis that patients benefited from the addition of docetaxel regardless of the clinical T stage. On the contrary, the SOX regimen is believed to be effective enough for Chinese patients in controlling lymph node metastasis,[@CIT0049] and there would be no extra benefit from the addition of docetaxel to the SOX regimen. Therefore, DOS did not show superiority to SOX as NAC when extensive lymph nodes were present, as is shown in the subgroup analysis from our study that patients with high clinical N stages (N2-3) did not obtain a benefit based on comparative analysis. Considering the p value was close to 0.05 in the statistical analysis, this finding should be interpreted with caution.

The consensus surrounding the extent of lymphadenectomy has been reached that D2 resection with TLND of at least 15 should be the standard for upfront radical surgery.[@CIT0016],[@CIT0050] However, the debate has been ongoing for the optimal lymphadenectomy strategy in the neoadjuvant therapy setting. An exploratory study of the optimal degree of lymph node dissection for LAGC after neoadjuvant chemoradiation showed that patients with D2 resection and TLND of 15 or more have better survival compared with those with D1 and TLND of fewer than 15.[@CIT0051] This is consistent with the results from our present study that OS was worse within the whole NAC population with TLND less than 16. In addition, the existence of residual tumor in LNs, rather than regression change in LNs, is meaningful for predicting the prognosis after NAC in GC patients.[@CIT0052] Therefore, despite the potential effects of tumor downstaging with perioperative therapy, a thorough logoregional lymphatic resection is still recommended. As a high volume center of GC, surgeons in our department are really proficient in performing the D2 radical gastrectomy with extensive lymphadenectomy, and the incidence of surgical complications was very low. This may partially explain the excellent OS in our data.

The DCF/mDCF regimen can be administered with varied drug dosage and cycle scheme. Comparatively, the dose intensity of docetaxel given in patients from Japan is higher than that in patients from Europe.[@CIT0029],[@CIT0053] A dose-finding study indicated that the recommended dose of the DOS regimen in patients with GC was docetaxel 52.5 mg/m^2^ and oxaliplatin 105 mg/m^2^ on day 1 and S-1 80 mg/m^2^ on day 1--14 of an every 21-day cycle.[@CIT0054] In the present study, we showed that the 3-week NAC regimen with docetaxel 75 mg/m^2^, oxaliplatin 130 mg/m^2^, and S-1 80 mg/m^2^ was well tolerated among the Chinese patients, although an increase in toxicity was observed. Actually, these disadvantages are well counterbalanced by the good response and survival benefit.

Some limitations of this study need to be illustrated. Firstly, SOX group included more patients deemed unfit (higher age) or unnecessary (less advanced tumor staging) for intensive chemotherapy than the DOS group, which resulted in a certain imbalance in the baseline characteristics between the two groups. Thus, we performed a PSM analysis to minimize the selection bias. Knowing that a retrospective study is underpowered, a prospective randomized trial is warranted to draw a firmer conclusion in future. Secondly, the patients included in this study are all Chinese, and most of them are resided in the coastal area of East China and Jiangxi Province. Therefore, the generalizability of the findings to population with different races, ethnics, or geographical environments may be limited. Finally, all surgical procedures in this study were performed by three senior surgeons (Q.C., W.W., and R.Y.) in a single center. Each of them has performed more than 1000 gastrectomy procedures in total as the head surgeon and has an annual gastrectomy volume of approximately 100. Therefore, it is not clear whether the conclusions can be extended to other surgeons with different levels of surgical experience.

In conclusion, DOS is superior to SOX as a NAC regimen in terms of tumor response, R0 resection rate and OS in patients with LAGC. Therefore, NAC with DOS is safe and feasible which is worth popularizing in clinical practice.
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